Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
29.66
+0.97 (3.38%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Janux Therapeutics Employees
Janux Therapeutics had 81 employees as of December 31, 2024. The number of employees increased by 17 or 26.56% compared to the previous year.
Employees
81
Change (1Y)
17
Growth (1Y)
26.56%
Revenue / Employee
$130,716
Profits / Employee
-$851,778
Market Cap
1.75B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Dec 31, 2023 | 64 | 4 | 6.67% |
| Dec 31, 2022 | 60 | 27 | 81.82% |
| Dec 31, 2021 | 33 | 21 | 175.00% |
| Dec 31, 2020 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
JANX News
- 13 days ago - Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout - Seeking Alpha
- 7 weeks ago - Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Business Wire
- 3 months ago - Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer - Business Wire
- 3 months ago - Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data - Seeking Alpha
- 3 months ago - Best-Performing Stocks Of 2024 - Seeking Alpha
- 4 months ago - Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire
- 4 months ago - Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
- 4 months ago - Janux Therapeutics Announces Proposed Public Offering - Business Wire